Selected research
Industry Research
Liposomal Amphoteracin B Industry Research Report 2026
Market perspective
The global Liposomal Amphoteracin B market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Liposomal Amphoteracin B is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Liposomal Amphoteracin B is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Liposomal Amphoteracin B is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Liposomal Amphoteracin B include Gilead Sciences and Cipla among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Liposomal Amphoteracin B market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Liposomal Amphoteracin B Market by Company
Gilead Sciences
Cipla
Liposomal Amphoteracin B Segment by Type
25mg
50mg
Liposomal Amphoteracin B Segment by Application
Hospital
Pharmacy
Liposomal Amphoteracin B Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liposomal Amphoteracin B market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Liposomal Amphoteracin B and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liposomal Amphoteracin B.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Liposomal Amphoteracin B manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Liposomal Amphoteracin B by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Liposomal Amphoteracin B in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 25mg
- 50mg
Applications
- Hospital
- Pharmacy
Companies covered
- Gilead Sciences
- Cipla
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Liposomal Amphoteracin B Market Size (2021-2032)
- 2.2.2 Global Liposomal Amphoteracin B Sales (2021-2032)
- 2.2.3 Global Liposomal Amphoteracin B Market Average Price (2021-2032)
- 2.3 Liposomal Amphoteracin B by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 25mg
- 2.3.3 50mg
- 2.4 Liposomal Amphoteracin B by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Pharmacy
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Liposomal Amphoteracin B Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Liposomal Amphoteracin B Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Liposomal Amphoteracin B Revenue of Manufacturers (2021-2026)
- 3.4 Global Liposomal Amphoteracin B Average Price by Manufacturers (2021-2026)
- 3.5 Global Liposomal Amphoteracin B Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Liposomal Amphoteracin B, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Liposomal Amphoteracin B, Product Type & Application
- 3.8 Global Manufacturers of Liposomal Amphoteracin B, Established Date
- 3.9 Global Liposomal Amphoteracin B Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Gilead Sciences
- 4.1.1 Gilead Sciences Company Information
- 4.1.2 Gilead Sciences Business Overview
- 4.1.3 Gilead Sciences Liposomal Amphoteracin B Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Gilead Sciences Liposomal Amphoteracin B Product Portfolio
- 4.1.5 Gilead Sciences Recent Developments
- 4.2 Cipla
- 4.2.1 Cipla Company Information
- 4.2.2 Cipla Business Overview
- 4.2.3 Cipla Liposomal Amphoteracin B Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Cipla Liposomal Amphoteracin B Product Portfolio
- 4.2.5 Cipla Recent Developments
5 Global Liposomal Amphoteracin B Market Scenario by Region
- 5.1 Global Liposomal Amphoteracin B Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Liposomal Amphoteracin B Sales by Region: 2021-2032
- 5.2.1 Global Liposomal Amphoteracin B Sales by Region: 2021-2026
- 5.2.2 Global Liposomal Amphoteracin B Sales by Region: 2027-2032
- 5.3 Global Liposomal Amphoteracin B Revenue by Region: 2021-2032
- 5.3.1 Global Liposomal Amphoteracin B Revenue by Region: 2021-2026
- 5.3.2 Global Liposomal Amphoteracin B Revenue by Region: 2027-2032
- 5.4 North America Liposomal Amphoteracin B Market Facts & Figures by Country
- 5.4.1 North America Liposomal Amphoteracin B Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Liposomal Amphoteracin B Sales by Country (2021-2032)
- 5.4.3 North America Liposomal Amphoteracin B Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Liposomal Amphoteracin B Market Facts & Figures by Country
- 5.5.1 Europe Liposomal Amphoteracin B Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Liposomal Amphoteracin B Sales by Country (2021-2032)
- 5.5.3 Europe Liposomal Amphoteracin B Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Liposomal Amphoteracin B Market Facts & Figures by Country
- 5.6.1 Asia Pacific Liposomal Amphoteracin B Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Liposomal Amphoteracin B Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Liposomal Amphoteracin B Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Liposomal Amphoteracin B Market Facts & Figures by Country
- 5.7.1 South America Liposomal Amphoteracin B Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Liposomal Amphoteracin B Sales by Country (2021-2032)
- 5.7.3 South America Liposomal Amphoteracin B Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Liposomal Amphoteracin B Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Liposomal Amphoteracin B Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Liposomal Amphoteracin B Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Liposomal Amphoteracin B Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Liposomal Amphoteracin B Sales by Type (2021-2032)
- 6.1.1 Global Liposomal Amphoteracin B Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Liposomal Amphoteracin B Sales Market Share by Type (2021-2032)
- 6.2 Global Liposomal Amphoteracin B Revenue by Type (2021-2032)
- 6.2.1 Global Liposomal Amphoteracin B Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Liposomal Amphoteracin B Revenue Market Share by Type (2021-2032)
- 6.3 Global Liposomal Amphoteracin B Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Liposomal Amphoteracin B Sales by Application (2021-2032)
- 7.1.1 Global Liposomal Amphoteracin B Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Liposomal Amphoteracin B Sales Market Share by Application (2021-2032)
- 7.2 Global Liposomal Amphoteracin B Revenue by Application (2021-2032)
- 7.2.1 Global Liposomal Amphoteracin B Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Liposomal Amphoteracin B Revenue Market Share by Application (2021-2032)
- 7.3 Global Liposomal Amphoteracin B Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Liposomal Amphoteracin B Value Chain Analysis
- 8.1.1 Liposomal Amphoteracin B Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Liposomal Amphoteracin B Production Mode & Process
- 8.2 Liposomal Amphoteracin B Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Liposomal Amphoteracin B Distributors
- 8.2.3 Liposomal Amphoteracin B Customers
9 Global Liposomal Amphoteracin B Analyzing Market Dynamics
- 9.1 Liposomal Amphoteracin B Industry Trends
- 9.2 Liposomal Amphoteracin B Industry Drivers
- 9.3 Liposomal Amphoteracin B Industry Opportunities and Challenges
- 9.4 Liposomal Amphoteracin B Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst